Table 2.

TIL characteristics (A) and objective response (B)

A. TIL characteristicsB. Objective response
Infused cells
PatientSite of biopsyTILs cryo before REPTreatment after surgeryaYoung-TIL days in cultureREP Fold expansionTotal (×109)CD8%CD4%γδ%CD8 (×109)Best clinical response RECIST v 1.0PFS monthsOS months
Responders, OR (n = 10)
 M15LNNoNone164,28486315510.727CR47+47+
 M17LNNoNone317,12514325722.535PR (NED)45+45+
 M20SCCryoNone344,1008289110.093PR1222
 M22SCCryoNone206,13911753470.262PR28+28+
 M24LNNoNone245,51511067200.174PR (NED)36+36+
 M26IMCryoNone176,5601319350.1122CR32+32+
 M31SCNoNone275,86011753470.262PR11.320
 M36IACryoVemurafenib306,16912055440.666PR8.225
 M42SCNoNone204,148838910.07CR22+22+
 M45LNCryoNone145,11810253440.354PR11.3+17+
Median225,69011453460.262NRNR
Range14–344,100–7,12582–1438–935–910–117–122
n (%)5 (50)1 (10)
Nonresponders, NR (n = 14)
 M14LNNoNone212,8568617820.315PD2.53.2
 M16SCCryoNone233,0756288110.254SD3.945+
 M18SCCryoNone179,9752008693.6172SD3.95.3
 M25LNNoNone296,35012755359.770SD3.85.5
 M27SCCryoVemurafenib244,9209848520.247PD2.03.5
 M29LNNoVemurafenib134,08082371051.030SD3.85.4
 M34LNNoNone245,5251109240.9101SD2.85.0
 M35SCCryoVemurafenib174,930986930.36SD3.117+
 M37SCCryoNone136,283125502916.962SD3.012
 M40IACryoNone193,9687828589.522SD3.714
 M43SCNoNone364,4559932670.232PD1.921+
 M46LNNoNone173,76975315413.523SD5.820+
 M47PleuraNoNone204,1738370280.223SD3.319+
 M51LNNoNone313,0556133490.420SD3.214+
Median214,3149242410.7303.313.1
Range13–362,856–9,97561–2006–924–930.2–516–172
n (%)6 (43)3 (21)
P (OR vs. NR)1.000.620.600.10.140.560.980.080.180.00010.02
Not evaluable (n = 1)
M50SCNoNone263,2056416820.910Na0.10.1
All patients (n = 25)
Median214,9209850470.3473.924.6
Range13–362,856–9,97561–2006–934–930–516–172
n (%)11 (44)4 (16)
  • Abbreviations: cryo, cryopreserved; IA, intra-abdominal; IM, intramuscular; LN, lymph node; NED, no evidence of disease; NR, nonresponders; OR, objective responders; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; REP, rapid expansion protocol; SC, subcutaneous; SD, stable disease.

  • aSystemic treatment administered between tumor resection (surgery) and TIL-ACT.